Napredna pretraga

Pregled bibliografske jedinice broj: 682987

Common genetic variation and antidepressant efficacy in major depressive disorder : a meta-analysis of three genome-wide pharmacogenetic studies


GENDEP Investigators; MARS Investigators; STAR*D Investigators
Common genetic variation and antidepressant efficacy in major depressive disorder : a meta-analysis of three genome-wide pharmacogenetic studies // American journal of psychiatry, 170 (2013), 2; 207-217 doi:10.1176/appi.ajp.2012.12020237 (međunarodna recenzija, članak, znanstveni)


Naslov
Common genetic variation and antidepressant efficacy in major depressive disorder : a meta-analysis of three genome-wide pharmacogenetic studies

Autori
GENDEP Investigators ; MARS Investigators ; STAR*D Investigators

Izvornik
American journal of psychiatry (0002-953X) 170 (2013), 2; 207-217

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Antidepressive agents; genome; genetics; major depressive disorder; pharmacogenetics; mars

Sažetak
Objective Indirect evidence suggests that common genetic variation contributes to individual differences in antidepressant efficacy among individuals with major depressive disorder, but previous studies may have been underpowered to detect these effects. Method A meta-analysis was performed on data from three genome-wide pharmacogenetic studies (the Genome-Based Therapeutic Drugs for Depression [GENDEP] project, the Munich Antidepressant Response Signature [MARS] project, and the Sequenced Treatment Alternatives to Relieve Depression [STAR*D] study), which included 2, 256 individuals of Northern European descent with major depressive disorder, and antidepressant treatment outcomes were prospectively collected. After imputation, 1.2 million single-nucleotide polymorphisms were tested, capturing common variation for association with symptomatic improvement and remission after up to 12 weeks of antidepressant treatment. Results No individual association met a genome-wide threshold for statistical significance in the primary analyses. A polygenic score derived from a meta-analysis of GENDEP and MARS participants accounted for up to approximately 1.2% of the variance in outcomes in STAR*D, suggesting a weakly concordant signal distributed over many polymorphisms. An analysis restricted to 1, 354 individuals treated with citalopram (STAR*D) or escitalopram (GENDEP) identified an intergenic region on chromosome 5 associated with early improvement after 2 weeks of treatment. Conclusions Despite increased statistical power accorded by meta-analysis, the authors identified no reliable predictors of antidepressant treatment outcome, although they did identify modest, direct evidence that common genetic variation contributes to individual differences in antidepressant response.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Projekt / tema
108-1081870-1880 - 1H-MRS promjene u predviđanju terapijskog odgovora, relapsa i povrata depresije (Neven Henigsberg, )

Ustanove
Medicinski fakultet, Zagreb

Autor s matičnim brojem:
Neven Henigsberg, (200094)

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • Social Science Citation Index (SSCI)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati